Tom Powles (@tompowles1) 's Twitter Profile
Tom Powles

@tompowles1

Interested in Urology Cancers, biomarkers and drug development.

ID: 1206580727296544769

calendar_today16-12-2019 14:24:22

1,1K Tweet

12,12K Followers

62 Following

Uromigos (@uromigos) 's Twitter Profile Photo

1/2 The Uromigos Score for MIBC. Neoadjuvant chemo & ICIs strongly supported (irrespective of PD-L1 status). Perioperative durva scores higher than adjuvant nivo in cisplatin eligibles (2.9 vs 2.1). TMT appears a reasonable alternative to surgery (1.9). Nivo and Pembro have

1/2 The Uromigos Score for MIBC. Neoadjuvant chemo & ICIs strongly supported (irrespective of PD-L1 status). Perioperative durva scores higher than adjuvant nivo in cisplatin eligibles (2.9 vs 2.1). TMT appears a reasonable alternative to surgery (1.9). Nivo and Pembro have
Uromigos (@uromigos) 's Twitter Profile Photo

2/2 many thanks to global contributors. We await other perioperative IO trials including EVP & DTEV which is likely to change everything.

2/2 many thanks to global contributors. We await other perioperative IO trials including EVP & DTEV which is likely to change everything.
Tres Uramigas (@tresuramigas) 's Twitter Profile Photo

🔵 #UromigosScore para MIBC: Respaldo a QT+ICIs neoadyuvante (indep PD-L1). Durva periop. > Nivo adyuvante en cis-elegible (2.9 vs 2.1). TMT alternativa razonable (1.9). Nivo/Pembro similares y opción en no elegibles.

Uromigos (@uromigos) 's Twitter Profile Photo

🚨 New episode alert! Joe Jacob joins the show to discuss the longer-term follow up of this cohort from SunRISe-1. We discuss definitions of CR and regulatory issues around drug approval in this space as well. 🎙️ GU Oncology Now: buff.ly/N5cAT6F 🍎 Apple Podcasts:

🚨 New episode alert! Joe Jacob joins the show to discuss the longer-term follow up of this cohort from SunRISe-1. We discuss definitions of CR and regulatory issues around drug approval in this space as well.

🎙️ GU Oncology Now: buff.ly/N5cAT6F
 🍎 Apple Podcasts:
Tom Powles (@tompowles1) 's Twitter Profile Photo

POTOMAC trial- Durvalumab + BCG shows positive results for DFS in high-risk NMIBC vs BCG alone. sasanlimab (CREST) also had an EFS advantage here: HR 0.68. Consistent results in early disease is compelling. IO tox is relevant in risk/benefit ratio. astrazeneca.com/media-centre/p…

POTOMAC trial- Durvalumab + BCG shows positive results for DFS in high-risk NMIBC vs BCG alone. sasanlimab (CREST) also had an EFS advantage here: HR 0.68. Consistent results in early disease is compelling. IO tox is relevant in risk/benefit ratio.   astrazeneca.com/media-centre/p…
Uromigos (@uromigos) 's Twitter Profile Photo

1/N Uromigos Tweet of the Month!! The Uromigos Score for Advanced Prostate Cancer We polled 24 prostate cancer experts from 13 countries regarding the value of different treatment options in various advanced prostate cancer disease states. 🇺🇸🇦🇺🇧🇷🇩🇪🇮🇹🇦🇹🇪🇸🇨🇭🇯🇵🇬🇧🇸🇬🇧🇪🇹🇷 Podcast

Uromigos (@uromigos) 's Twitter Profile Photo

3/N Take Home Points in Metastatic Castrate Resistant Prostate Cancer (mCRPC) as first line therapy after ADT + ARPI with no prior docetaxel: · Docetaxel scores high independent of HRR status · PARPi monotherapy favored over all other options including PARPi + ARPI in BRCA

3/N
Take Home Points in Metastatic Castrate Resistant Prostate Cancer (mCRPC) as first line therapy after ADT + ARPI with no prior docetaxel:

· Docetaxel scores high independent of HRR status

· PARPi monotherapy favored over all other options including PARPi + ARPI in BRCA
Tres Uramigas (@tresuramigas) 's Twitter Profile Photo

🔐(1/4) CPRCm según el #Uromigoscore: 1️⃣ línea tras TDA + ARPI: ✅ Docetaxel recibe puntuaciones altas en todos los subgrupos moleculares, independientemente del estado HRR. ❌ Cambiar de ARPI: estrategia poco valorada. Uromigos OncoAlert

🔐(1/4) CPRCm según el #Uromigoscore:

1️⃣ línea tras TDA + ARPI:

✅ Docetaxel recibe puntuaciones altas en todos los subgrupos moleculares, independientemente del estado HRR.
❌ Cambiar de ARPI: estrategia poco valorada.

<a href="/Uromigos/">Uromigos</a> <a href="/OncoAlert/">OncoAlert</a>
Annals of Oncology (@annals_oncology) 's Twitter Profile Photo

🆕ESMO guideline podcast🎧: Annals of Oncology Editor-in-Chief Tom Powles discusses the ESMO ESMO Clinical Practice Guideline for hepatocellular carcinoma with Arndt Vogel tinyurl.com/msfbh7fe For the full Clinical Practice Guideline see doi.org/10.1016/j.anno…

Uromigos (@uromigos) 's Twitter Profile Photo

🚨 New episode alert! silke gillessen and Christopher Sweeney, MBBS join us to discuss our latest 'Uromigos Score' in which experts score the value of treatments for advanced prostate cancer. Expect some interesting themes and insights. 🎙️ GU Oncology Now: buff.ly/GzQAw1J 🍎

🚨 New episode alert! <a href="/Silke_Gillessen/">silke gillessen</a> and <a href="/ChrisSweens1/">Christopher Sweeney, MBBS</a> join us to discuss our latest 'Uromigos Score' in which experts score the value of treatments for advanced prostate cancer. Expect some interesting themes and insights. 

🎙️ GU Oncology Now: buff.ly/GzQAw1J
 🍎
philipp ivanyi (@ivanyiphilipp) 's Twitter Profile Photo

Published! Previliged to be a Part of SUNNIFORCAST! World largest ranomized trial on #non-ccRCC #kidney cancer deiven by Academia #MHH

Published! Previliged to be a Part of SUNNIFORCAST! World largest ranomized trial on #non-ccRCC #kidney cancer deiven by Academia #MHH
Annals of Oncology (@annals_oncology) 's Twitter Profile Photo

🆕article in press: Pembrolizumab plus enzalutamide and androgen deprivation therapy vs placebo plus enzalutamide and androgen deprivation therapy for mHSPC: the randomized, double-blind, phase III KEYNOTE-991 study Christian Gratzke doi.org/10.1016/j.anno…

🆕article in press: Pembrolizumab plus enzalutamide and androgen  deprivation therapy vs placebo plus enzalutamide and androgen  deprivation therapy for mHSPC:  the randomized, double-blind, phase III KEYNOTE-991 study <a href="/cgratzke/">Christian Gratzke</a> 
doi.org/10.1016/j.anno…
Barts Experimental Cancer Medicine Centre (@bartsecmc) 's Twitter Profile Photo

Our International Clinical Trials Day event is happening now! Organised by our @bartsecmc patient group. You are welcome to pop in to West Wing and listen to our speakers. Up first is Tom Powles talking all about personalised cancer vaccines 💉🔬

Our International Clinical Trials Day event is happening now! Organised by our @bartsecmc patient group. You are welcome to pop in to West Wing and listen to our speakers. Up first is <a href="/tompowles1/">Tom Powles</a> talking all about personalised cancer vaccines 💉🔬
Barts Experimental Cancer Medicine Centre (@bartsecmc) 's Twitter Profile Photo

Thank you to everyone who came and took part in our International Clinical Trials Day event! If you are interested in keeping up to date with our events, please send us message or email [email protected]ECMC Network (@ecmc-uk.bsky.social) Barts Health

Thank you to everyone who came and took part in our International Clinical Trials Day event! If you are interested in keeping up to date with our events, please send us message or email BartsECMC@qmul.ac.uk ✨ <a href="/ECMC_UK/">ECMC Network (@ecmc-uk.bsky.social)</a> <a href="/NHSBartsHealth/">Barts Health</a>